The market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,
IN VITRO DIAGNOSTICS Financings Vermillion Inc. Vermillion Inc. grossed $5.6mm through the private sale of 3.75mm common shares at $1.40 (a 6% premium). Investors also received five-year warrants
New At The Helm Company Changes ALI , Faraz To: REGENXBIO Inc. , CBO (March) From: bluebird bio Inc., VP, Head, Global Commercial Dev. & External Affairs Phone: 240-552-8181 BLOOM , Kenneth J.